Events According to Revascularization Modality in the ISCHEMIA Trial

The main studies carried out on patients with chronic coronary syndromes (CCS), such as the MASS II, COURAGE, BARI 2D and FAME-2, failed to show benefits in terms of mortality with the invasive approach. 

Eventos según modo de revascularización en el Ischemia Trial

The ISCHEMIA, a large randomized study including patients with moderate to severe ischemia, with without left main disease and with acceptable or no angina, also failed to show benefits as to reducing the risk of ischemic events when opting for an invasive strategy (INV) vs. a conservative strategy (CON) with medical treatment at mean 3.2 years.

Of the 2054 INV patients, 74.1% received PCI, while 25.8% opted for CABG. An ad-hoc analysis of the ISCHEMIA compared events related to INV-PCI and INV CABG, taking into account revascularization modality was not random. The aim of this study was to assess the risk of early and late events associated to each strategy. Primary end point was a composite of cardiovascular death, myocardial infarction (MI), hospitalization for unstable angina, cardiac failure or resuscitated cardiac arrest. 

The analysis looked at INV-MED (from randomization to revascularization), INV-PCI and INV-CABG strategy outcomes, and compared them to the CON strategy outcomes. They analyzed events at 30 days (early) and beyond 30 days (late).

Read also: Coronary Artery Disease in TAVR: Unsolved Dilemma.

Mean time from randomization to revascularization was 22 days for PCI and 44 days for CABG. Of the 512 INV-CABG patients, 16.4% experienced primary end outcomes at mean 2.85 years, with 57.1% of these events occurring within 30 days (83.3% were MI). Of the 1500 INV-PCI, 9.8% presented primary end outcomes at mean 2.94 years, with 21.1% early occurrence (77.4% of these early events were MI). When comparing against the 2591 CON patients, 13.6% presented primary end outcomes, with an early occurrence of 6.3%.

Cumulative primary end point incidence at long term in MED, PCI and CABG was similar at secondary analysis. We should note that periprocedural MI was the only event in 40.5% of INV-CABG cases and in 16.3% of INV-PCI (separately). INV-PCI and INV-CABG were associated with greater early risk and lower late risk vs. CON.

Conclusions

Revascularization with CABG and PCI in INV patients was associated with higher incidence of cardiovascular events, especially periprocedural MI. However, this event incidence saw a reduction at long term vs. the conservative strategy. We should not overlook the non-random nature of these outcomes, especially considering that patients undergoing CABG had more severe CAD, which leads to higher adverse outcomes. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial.

Reference: Redfors, B, Stone, G, Alexander, J. et al. Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial. J Am Coll Cardiol. 2024 Feb, 83 (5) 549–558.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....